We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study.
- Authors
Wang, David; Hughes-Medlicott, Natalie; Klingler, Lilian; Wang, Yi; Hung, Noelyn; Duffull, Stephen; Hung, Tak; Glue, Paul; Qin, Albert; Kwan, Rudolf; Chan, Wing-Kai; Jackson, Christopher
- Abstract
Introduction: Docetaxel, a taxane used in the treatment of solid tumours, exerts pharmacological activity when in its unbound form. We report a sensitive assay to quantify unbound docetaxel after oral administration of docetaxel plus encequidar (oDox+E). Unbound drug quantification is important due to its direct correlation with drug-related toxicity and therapeutic efficacy. We improve on the sensitivity of current assay methods and demonstrate the utility of the assay on a novel formulation of oral docetaxel. Methods: Ultrafiltration followed by high-performance liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) was utilized. Long-term stability, precision, accuracy, and recovery experiments were conducted to validate the assay. Additionally, patient samples from a Phase I dose-escalation pharmacokinetic study were analyzed using the developed assay. Results: The assay method exhibited long-term stability with an observed change between 0.8 and 6.9% after 131 days of storage at −60 °C. Precision and accuracy quality controls met the FDA acceptance criteria. An average recovery of 88% was obtained. Patient sample analysis demonstrated successful implementation of the assay. Conclusion: A validated sensitive assay was developed with an LLOQ of 0.084 ng/mL using 485 µL of human plasma. The sensitivity of the assay allowed quantification of unbound docetaxel concentrations in an early-phase oDox+E clinical study to compare it against IV docetaxel using pharmacokinetic modelling. Successful development of oDox+E represents an opportunity to replace the current IV docetaxel regimen with an oral regimen with lower cost, decreased side effects, and improve patient quality of life and experience.
- Subjects
UNITED States. Food &; Drug Administration; DOCETAXEL; LIQUID chromatography-mass spectrometry; ORAL drug administration; ULTRAFILTRATION; HIGH performance liquid chromatography; TANDEM mass spectrometry
- Publication
Pharmaceutics, 2024, Vol 16, Issue 5, p602
- ISSN
1999-4923
- Publication type
Article
- DOI
10.3390/pharmaceutics16050602